| 1 |
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy John Perren et al. · New England Journal of Medicine
Open access |
28 Dec 2011 |
2,183 |
| 2 |
Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria)
Jean‐Jacques Labat, Thibault Riant, Roger Robert et al. · Neurourology and Urodynamics
|
7 Sep 2007 |
495 |
| 3 |
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
Emmanuel Ekanem et al. · Nature Medicine
Open access139 authors |
Jul 2024 |
484 |
| 4 |
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Charles E. Geyer et al. · Annals of Oncology
Open access609 authors |
10 Oct 2022 |
477 |
| 5 |
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al. · Blood
Open access |
24 Sep 2018 |
424 |
| 6 |
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I. Ray-Coquard et al. · Annals of Oncology
Open access |
19 May 2023 |
364 |
| 7 |
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer et al. · The Lancet Oncology
Open access187 authors |
16 Apr 2020 |
167 |
| 8 |
Building a replicated logging system with Apache Kafka
Guozhang Wang, Joel Koshy, Sriram Subramanian et al. · Proceedings of the VLDB Endowment
|
Aug 2015 |
164 |
| 9 |
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata et al. · The Lancet Oncology
|
Feb 2021 |
154 |
| 10 |
Guidelines for the Primary Care of Lesbian, Gay, and Bisexual People: A Systematic Review
Ruth McNair, Kelsey Lee Hegarty · The Annals of Family Medicine
ReviewOpen access |
Nov 2010 |
136 |
| 11 |
Clinical and biological features in PIEZO1 -hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients
Véronique Picard et al. · Haematologica
Open access |
17 Jan 2019 |
129 |
| 12 |
Flash storage disaggregation
Ana Klimovic, Christos Kozyrakis, Eno Thereska et al.
Conference paper |
12 Apr 2016 |
123 |
| 13 |
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier P Leleu et al. · Nature Medicine
Open access |
3 Jun 2024 |
116 |
| 14 |
Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial
Isabel Deisenhofer et al. · Nature Medicine
Open access |
14 Feb 2025 |
114 |
| 15 |
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
Thomas A. Walter et al. · European Journal of Cancer
|
11 May 2017 |
112 |
| 16 |
The Natural History of Clinical Operational Tolerance After Kidney Transplantation Through Twenty-Seven Cases
Sophie Brouard et al. · American Journal of Transplantation
Open access |
13 Sep 2012 |
106 |
| 17 |
Ratings of Physician Communication by Real and Standardized Patients
Kevin A Fiscella, Peter John Franks, Malathi Srinivasan et al. · The Annals of Family Medicine
Open access |
Mar 2007 |
96 |
| 18 |
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Toon Van Gorp et al. · Annals of Oncology
Open access |
14 Sep 2024 |
93 |
| 19 |
Adding corticosteroids to the pudendal nerve block for pudendal neuralgia: a randomised, double‐blind, controlled trial
JJ Labat, Thibault Riant, A. Lassaux et al. · BJOG An International Journal of Obstetrics & Gynaecology
Open access |
27 Jul 2016 |
88 |
| 20 |
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
Claire Falandry et al. · JAMA Oncology
Open access |
22 Apr 2021 |
84 |
| 21 |
The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression
Juliette Eugène et al. · Modern Pathology
Open access |
13 Aug 2019 |
80 |
| 22 |
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing
Elodie Girard et al. · International Journal of Cancer
Open access |
10 Oct 2018 |
80 |
| 23 |
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
S. Vincent Rajkumar, Jean Luc Harousseau · Blood
Open access |
14 Oct 2016 |
79 |
| 24 |
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
Jean‐Yves Pierga et al. · Annals of Oncology
Open access |
11 Oct 2016 |
73 |
| 25 |
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
Anne-Sophie Chrétien et al. · Frontiers in Immunology
Open access |
29 May 2017 |
70 |
| 26 |
How I treat first relapse of myeloma
Jean Luc Harousseau, Michel Attal · Blood
Open access |
5 Jul 2017 |
68 |
| 27 |
Recurrences of Atrial Fibrillation Despite Durable Pulmonary Vein Isolation: The PARTY-PVI Study
Karim Bénali et al. · Circulation Arrhythmia and Electrophysiology
Open access |
20 Feb 2023 |
67 |
| 28 |
Endoscopic or arthroscopic iliopsoas tenotomy for iliopsoas impingement following total hip replacement. A prospective multicenter 64-case series
W. Guicherd, Nicolas Bonin, T. Gicquel et al. · Orthopaedics & Traumatology Surgery & Research
Open access |
13 Sep 2017 |
65 |
| 29 |
Combining intra‐dialytic exercise and nutritional supplementation in malnourished older haemodialysis patients: Towards better quality of life and autonomy
Dan Hristea, Thibault Deschamps, Anne Paris et al. · Nephrology
|
18 Feb 2016 |
65 |
| 30 |
Recommendations on the management of pudendal nerve entrapment syndrome: A formalised expert consensus
Amélie Levesque et al. · European Journal of Pain
|
13 Oct 2021 |
59 |
| 31 |
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Leonard Friedlander et al. · The Lancet Oncology
|
15 Apr 2021 |
58 |
| 32 |
Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial
Karim Asehnoune et al. · BMJ
Open access |
2 Jun 2021 |
55 |
| 33 |
NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML
Anne-Sophie Chrétien, Raynier Devillier, Cyril Fauriat et al. · OncoImmunology
Open access |
24 Mar 2017 |
52 |
| 34 |
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lodé, Audrey Ménard, Laurent Flet et al. · Haematologica
Open access |
21 Dec 2017 |
50 |
| 35 |
Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3′-Deoxy-3′-18F-Fluorothymidine PET Images in Lung Cancer
S. Thureau et al. · Journal of Nuclear Medicine
Open access |
5 Aug 2013 |
50 |
| 36 |
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
Rémy Gressin et al. · Haematologica
Open access |
31 Aug 2018 |
48 |
| 37 |
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia
Anne-Sophie Chrétien, Cyril Fauriat, Florence Orlanducci et al. · Oncotarget
Open access |
10 May 2017 |
48 |
| 38 |
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium
Maria Alice Franzoi, Arlindo Rebelo Ferreira, Antoine Lemaire et al. · The Lancet Regional Health - Europe
Open access |
31 Jul 2024 |
47 |
| 39 |
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
Marta Sobas et al. · Blood Advances
Open access |
8 Jul 2022 |
47 |
| 40 |
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer
Marc Pujalte‐Martin, Delphine Borchiellini, Brice Thamphya et al. · Clinical Genitourinary Cancer
Open access |
17 Sep 2021 |
44 |
| 41 |
Surveillance of leishmaniasis cases from 15 European centres, 2014 to 2019: a retrospective analysis
Gert Van der Auwera et al. · Eurosurveillance
Open access |
27 Jan 2022 |
43 |
| 42 |
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
Roberto Josè Pessoa de Magalhães Filho et al. · Clinical Lymphoma Myeloma & Leukemia
Open access |
29 Aug 2018 |
43 |
| 43 |
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Alice Boilève, Marc Hilmi, Paul Gougis et al. · European Journal of Cancer
Open access |
3 Dec 2020 |
41 |
| 44 |
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Isabelle Laure Ray-Coquard, Alexandra F. Leary, Sandro Pignata et al. · Annals of Oncology
Open access |
Sep 2022 |
40 |
| 45 |
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial
Arnaud Pigneux et al. · Journal of Clinical Oncology
|
27 Sep 2018 |
40 |
| 46 |
Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
Françoise Kraeber‐Bodéré et al. · The Lancet Haematology
|
8 Dec 2016 |
40 |
| 47 |
ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification
Charles Ronsin et al. · American Journal of Kidney Diseases
|
11 Jun 2021 |
39 |
| 48 |
Clinical impact of an additional left ventricular lead in cardiac resynchronization therapy nonresponders: The V3 trial
Pierre Bordachar, Daniel Cabeza Gras, Nicolas Clémenty et al. · Heart Rhythm
|
26 Dec 2017 |
39 |
| 49 |
The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
John G.F. Cleland, Michael R. Bristow, Nicholas Freemantle et al. · European Journal of Heart Failure
Open access |
May 2022 |
36 |
| 50 |
Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients
Romain Guéry, Stephen L. Walker, Gundel Harms et al. · PLoS neglected tropical diseases
Open access |
13 Oct 2021 |
36 |